STALICLA SA
Industry
- Pharmaceuticals
- Biotechnology
- Drug Discovery Technologies
See more in Biomedtracker
Latest on STALICLA SA
Scrip
• By Mandy Jackson
Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the la
Scrip
• By Kevin Grogan
Switzerland's STALICLA SA has bagged the rights to Novartis AG 's mavoglurant, which has had a complicated clinical development history, with the initial aim of putting the drug into late-stage tri
Scrip
• By Joseph Haas
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Terray Inks Initial Partnership With Ca